Applied Therapeutics Inc (APLT) - Total Liabilities
Based on the latest financial reports, Applied Therapeutics Inc (APLT) has total liabilities worth $34.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Applied Therapeutics Inc (APLT) equity growth momentum to track the company's year-over-year net asset growth rate.
Applied Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Applied Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Applied Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pasinex Resources Limited
F:PNX
|
Germany | €6.84 Million |
|
GigaMedia Limited
F:GIFN
|
Germany | €2.41 Million |
|
Dhunseri Tea & Industries Limited
NSE:DTIL
|
India | Rs4.36 Billion |
|
Imaspro Corporation Bhd
KLSE:7222
|
Malaysia | RM7.38 Million |
|
Locksley Resources Ltd
AU:LKY
|
Australia | AU$1.07 Million |
|
Buxton Resources Ltd
AU:BUX
|
Australia | AU$300.90K |
|
PeterLabs Holdings Bhd
KLSE:0171
|
Malaysia | RM21.70 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
Sweden | Skr83.83 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Applied Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Applied Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -62.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Applied Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Applied Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Applied Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $29.68 Million | -58.76% |
| 2023-12-31 | $71.98 Million | +109.84% |
| 2022-12-31 | $34.30 Million | +25.40% |
| 2021-12-31 | $27.35 Million | +21.21% |
| 2020-12-31 | $22.57 Million | +42.99% |
| 2019-12-31 | $15.78 Million | +256.41% |
| 2018-12-31 | $4.43 Million | -38.90% |
| 2017-12-31 | $7.25 Million | -- |
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more